抑制肾酶通过促进T细胞活化驱动肿瘤排斥
本研究在两种小鼠黑色素瘤模型中探讨肾酶(RNLS)抑制对肿瘤微环境的影响。RNLS敲除小鼠注射野生型黑色素瘤细胞后肿瘤被排斥,该效应依赖T细胞;抗RNLS抗体m28增强T细胞浸润与活化并产生免疫记忆。抗RNLS抗体联合抗PD-1在两种侵袭性小鼠黑色素瘤模型中较单药治疗带来更优的肿瘤缩小和生存;在PD-1抑制剂治疗患者的前置样本中,高RNLS表达与生存期缩短相关(log-rank P=0.006)。
要点
- RNLS敲除小鼠注射野生型黑色素瘤细胞后排斥肿瘤,该效应需要T细胞参与。
- 抗RNLS抗体m28增强瘤内T细胞浸润与活化,并产生免疫记忆。
- 抗RNLS抗体联合抗PD-1在两种小鼠黑色素瘤模型中优于单药。
核心结论
- RNLS敲除以T细胞依赖的方式导致黑色素瘤肿瘤消退。
- 抗RNLS抗体在两种对PD-1抑制剂耐药的侵袭性小鼠黑色素瘤模型中增强抗PD-1活性,支持开发抗RNLS抗体联合PD-1抑制剂作为对PD-1反应不佳黑色素瘤的新方法。
研究设计与样本
- 研究使用两种不同的小鼠黑色素瘤模型,在RNLS敲除(KO)或野生型(WT)小鼠中进行。
- 野生型小鼠接受抗RNLS抗体m28治疗,联合或不联合抗PD-1。
- 使用10X单细胞RNA测序识别治疗组间的转录差异,并通过流式细胞术检测肿瘤细胞含量。
- 对接受免疫治疗的患者样本通过定量免疫荧光检测RNLS表达。
主要发现
- RNLS KO小鼠注射野生型黑色素瘤细胞后排斥肿瘤,支持TME中细胞RNLS的重要性;该效应被抗CD3减弱。
- MØ特异性RNLS消融不足以消除肿瘤形成。
- 抗RNLS抗体治疗荷黑色素瘤小鼠导致T细胞浸润和活化增强,并在再次注射黑色素瘤细胞时产生免疫记忆。
- 单细胞水平上,抗RNLS抗体治疗增加MØ、中性粒细胞和淋巴细胞的肿瘤密度,并增加自然杀伤细胞和T细胞中IFNγ和颗粒酶B的表达;瘤内FoxP3+CD4细胞减少。
- 在两种不同小鼠黑色素瘤模型中,抗RNLS抗体联合抗PD-1治疗的荷瘤小鼠较任一单药治疗有更优的肿瘤缩小和生存;在PD-1抑制剂治疗患者的前置样本中,高RNLS表达与生存期缩短相关(log-rank P=0.006),独立于其他预后变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although programmed cell death protein 1 (PD-1) inhibitors have revolutionised treatment for advanced melanoma, not all patients respond. We previously showed that inhibition of the flavoprotein renalase (RNLS) in preclinical melanoma models decreases tumour growth. We hypothesised that RNLS inhibition promotes tumour rejection by effects on the tumour microenvironment (TME). METHODS: We used two distinct murine melanoma models, studied in RNLS knockout (KO) or wild-type (WT) mice. WT mice were treated with the anti-RNLS antibody, m28, with or without anti-PD-1. 10X single-cell RNA-sequencing was used to identify transcriptional differences between treatment groups, and tumour cell content was interrogated by flow cytometry. Samples from patients treated with immunotherapy were examined for RNLS expression by quantitative immunofluorescence. RESULTS: RNLS KO mice injected with wild-type melanoma cells reject their tumours, supporting the importance of RNLS in cells in the TME. This effect was blunted by anti-cluster of differentiation 3. However, MØ-specific RNLS ablation was insufficient to abrogate tumour formation. Anti-RNLS antibody treatment of melanoma-bearing mice resulted in enhanced T cell infiltration and activation and resulted in immune memory on rechallenging mice with injection of melanoma cells. At the single-cell level, treatment with anti-RNLS antibodies resulted in increased tumour density of MØ, neutrophils and lymphocytes and increased expression of IFNγ and granzyme B in natural killer cells and T cells. Intratumoural Forkhead Box P3 + CD4 cells were decreased. In two distinct murine melanoma models, we showed that melanoma-bearing mice treated with anti-RNLS antibodies plus anti-PD-1 had superior tumour shrinkage and survival than with either treatment alone. Importantly, in pretreatment samples from patients treated with PD-1 inhibitors, high RNLS expression was associated with decreased survival (log-rank P = 0.006), independent of other prognostic variables. CONCLUSIONS: RNLS KO results in melanoma tumour regression in a T-cell-dependent fashion. Anti-RNLS antibodies enhance anti-PD-1 activity in two distinct aggressive murine melanoma models resistant to PD-1 inhibitors, supporting the development of anti-RNLS antibodies with PD-1 inhibitors as a novel approach for melanomas poorly responsive to anti-PD-1.
引用
- Guo X, Jessel S, Qu R, et al. Inhibition of renalase drives tumour rejection by promoting T cell activation. Eur J Cancer. 2022. PMID: 35219026. doi:10.1016/j.ejca.2022.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。